244 related articles for article (PubMed ID: 30675284)
1. CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6.
Yoshiba T; Saga Y; Urabe M; Uchibori R; Matsubara S; Fujiwara H; Mizukami H
Oncol Lett; 2019 Feb; 17(2):2197-2206. PubMed ID: 30675284
[TBL] [Abstract][Full Text] [Related]
2. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.
Zhen S; Hua L; Takahashi Y; Narita S; Liu YH; Li Y
Biochem Biophys Res Commun; 2014 Aug; 450(4):1422-6. PubMed ID: 25044113
[TBL] [Abstract][Full Text] [Related]
4. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of AAV-delivered CRISPR/Cas9-based degradation of the HPV18-E6 gene in HeLa cells.
Noroozi Z; Shamsara M; Valipour E; Esfandyari S; Ehghaghi A; Monfaredan A; Azizi Z; Motevaseli E; Modarressi MH
Sci Rep; 2022 Feb; 12(1):2224. PubMed ID: 35140292
[TBL] [Abstract][Full Text] [Related]
6. Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells.
Cheng YX; Chen GT; Yang X; Wang YQ; Hong L
Curr Med Sci; 2018 Apr; 38(2):212-221. PubMed ID: 30074178
[TBL] [Abstract][Full Text] [Related]
7. In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line.
Zhen S; Lu JJ; Wang LJ; Sun XM; Zhang JQ; Li X; Luo WJ; Zhao L
Transl Oncol; 2016 Dec; 9(6):498-504. PubMed ID: 27816686
[TBL] [Abstract][Full Text] [Related]
8. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
[TBL] [Abstract][Full Text] [Related]
9. Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells.
Yu L; Wang X; Zhu D; Ding W; Wang L; Zhang C; Jiang X; Shen H; Liao S; Ma D; Hu Z; Wang H
Onco Targets Ther; 2015; 8():37-44. PubMed ID: 25565864
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer.
Zhen S; Li X
Cell Physiol Biochem; 2017; 44(6):2455-2466. PubMed ID: 29268281
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral Vectors Armed with PAPILLOMAVIRUs Oncogene Specific CRISPR/Cas9 Kill Human-Papillomavirus-Induced Cervical Cancer Cells.
Ehrke-Schulz E; Heinemann S; Schulte L; Schiwon M; Ehrhardt A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708897
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness.
Leung TH; Tang HW; Siu MK; Chan DW; Chan KK; Cheung AN; Ngan HY
J Pathol; 2018 Feb; 244(2):151-163. PubMed ID: 28944962
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells
Pirouzfar M; Amiri F; Dianatpour M; Takhshid MA
EXCLI J; 2020; 19():170-182. PubMed ID: 32194363
[TBL] [Abstract][Full Text] [Related]
14. Blocking activity of the HPV18 virus in cervical cancer cells using the CRISPR/Cas9 system.
Wang J; Guo M; Wang Q; Dang J; Liu X; Jin Z
Int J Clin Exp Pathol; 2018; 11(8):4230-4235. PubMed ID: 31949818
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-AAV Mediated Knock-in at NRL Locus in Human Embryonic Stem Cells.
Ge X; Xi H; Yang F; Zhi X; Fu Y; Chen D; Xu RH; Lin G; Qu J; Zhao J; Gu F
Mol Ther Nucleic Acids; 2016 Nov; 5(11):e393. PubMed ID: 27898094
[TBL] [Abstract][Full Text] [Related]
16. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia.
Zhao H; Li Y; He L; Pu W; Yu W; Li Y; Wu YT; Xu C; Wei Y; Ding Q; Song BL; Huang H; Zhou B
Circulation; 2020 Jan; 141(1):67-79. PubMed ID: 31779484
[TBL] [Abstract][Full Text] [Related]
17.
Li Q; Su J; Liu Y; Jin X; Zhong X; Mo L; Wang Q; Deng H; Yang Y
Mol Ther Methods Clin Dev; 2021 Mar; 20():652-659. PubMed ID: 33718515
[TBL] [Abstract][Full Text] [Related]
18.
Lau CH; Suh Y
F1000Res; 2017; 6():2153. PubMed ID: 29333255
[TBL] [Abstract][Full Text] [Related]
19. CD71
Leung TH; Tang HW; Siu MK; Chan DW; Chan KK; Cheung AN; Ngan HY
Mol Cancer Res; 2019 Sep; 17(9):1867-1880. PubMed ID: 31235657
[TBL] [Abstract][Full Text] [Related]
20. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
